Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Strathcona Resources (OTCPK:STHRF) said Friday it formally launched its offer to acquire MEG Energy (OTCPK:MEGEF) that values ...

BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Meanwhile, UBS maintained a Buy rating on Eli Lilly, setting a price target of $1,050, and BMO Capital reiterated an Outperform rating with a $900 price target following the SiteOne deal.

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Meanwhile, Eli Lilly has also made a strategic move by agreeing to acquire SiteOne Therapeutics in a deal valued at up to $1 billion. This acquisition aims to enhance Lilly’s non-opioid pain ...

The acquisition grants Eli Lilly and Company (NYSE:LLY) access to SiteOne’s pipeline, including its lead compound currently in Phase 2 trials. Analyst Evan Seigerman of BMO described the ...

Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other ...